Business
Telo Genomics Launches a Minimal Residual Disease Clinical Trial in Multiple Myeloma
Toronto, Ontario--(Newsfile Corp. - November 9, 2022) - Telo Genomics Corp. (TSXV: TELO) (OTC...
About this update from Telo Genomics Corp.
[{"type":"text","content":"Telo Genomics Launches a Minimal Residual Disease Clinical Trial in Multiple MyelomaToronto, Ontario--(Newsfile Corp. - November 9, 2022) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the \"Company\" or \"TELO\") is pleased to announce today that it is launching a clinical trial to monitor multiple myeloma disease progression in post-treated patients, by measuring and profiling the minimal residual disease (\"MRD\") in these patients. The clinical trial is being conducted in collaboration with McGill University and the Jewish General Hospital in Montreal, Canada. The trial is listed on the website of the National Library of Medicine (clinicaltrials.gov): NCT05530096 (https://clinicaltrials.gov/ct2/show/NCT05530096).The study will be conducted prospectively on diagnosed MM patients eligible for bone marrow transplantation, it has two objectives that will potentially enable TELO to develop two prognostic tests for monitoring myeloma MRD. MRD refers to myeloma plasma cells that remained in the patient's system post treatment. The two objectives include: i) quantify the number of MRD cells circulating in the patient's blood post treatment, and ii) profile the circulating MRD cells using our TeloView technology to assess disease aggressiveness in individual MRD cells. The two MRD tests for MM are designed to be liquid biopsy-based, which is at the forefront of precision medicine. Monitoring MRD in oncology is evolving to be an important prognostic tool for assessing the depth of a patient's response to treatment; it can also help in identifying patients at higher risk of relapse and potentially guide response-based treatment paradigms in several hematological disorders including MM. In North America there are approximately 180,000 MM patients receiving treatment at any time across the different stages of the disease. Most of these patients may benefit from ongoing monitoring of treatment response using MRD assessment. To date, the prognostic power of MRD assessment is not fully realized in the clinic for MM patients, this is due to the limited capability of the current technologies, which can only inform on MRD cell count (enumeration). Enumeration alone was proven over the years to be inadequate in providing accurate representation of the risk of disease progression. Furthermore, each of the current MRD assessment technologies ...